<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357693</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 280/12</org_study_id>
    <nct_id>NCT02357693</nct_id>
  </id_info>
  <brief_title>Neurokinin Receptor Antagonist Associated to Ondansetron in PONV</brief_title>
  <acronym>PONV</acronym>
  <official_title>Effect of the Association of Neurokinin-1 Receptor Antagonist Aprepitant to Dexamethasone/Ondansetron in the Incidence of Postoperative Nausea and Vomiting in High Risk Apfel Score Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether patients at high risk for postoperative
      nausea and vomiting can benefit from aprepitant, ondansetron and dexamethasone in the
      perioperative period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High risk surgical patients for PONV, scheduled for laparoscopic surgery will be distributed
      in two groups: Group I will receive aprepitant 80 mg per os and Group II will receive placebo
      per os, one hour before surgery. In the operating room, patients will be submitted to
      combined intravenous general anesthesia plus spinal anesthesia. All patients will receive
      dexamethasone 4 mg and ondansetron 4 mg intravenously during the surgical procedure. After
      surgery, patients will be monitored for pain, nausea and vomiting during 24 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of nausea and vomiting in postoperative period</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>aprepitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aprepitant 80 mg one hour before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo one hour before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant</intervention_name>
    <description>Aprepitant or placebo will be administered to the patient before surgery</description>
    <arm_group_label>aprepitant</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Emend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  high risk patients for nausea and vomiting

        Exclusion Criteria:

          -  cardiovascular disease, or hypersensibility to any of the drugs involved in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hazem a Ashmawi, phD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angela Maria Sousa</name>
      <address>
        <city>Sao Paulo</city>
        <state>São Paulo</state>
        <zip>01403010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Kawano H, Matsumoto T, Hamaguchi E, Manabe S, Nakagawa M, Yamada A, Fujimoto M, Tada F. Antiemetic efficacy of combined aprepitant and dexamethasone in patients at high-risk of postoperative nausea and vomiting from epidural fentanyl analgesia. Minerva Anestesiol. 2015 Apr;81(4):362-8. Epub 2014 Sep 15.</citation>
    <PMID>25220550</PMID>
  </results_reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>August 24, 2015</last_update_submitted>
  <last_update_submitted_qc>August 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nausea, postoperative</keyword>
  <keyword>postoperative nausea</keyword>
  <keyword>postoperative vomiting</keyword>
  <keyword>vomiting, postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Neurokinin A</mesh_term>
    <mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 29, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

